PPARligands evoke a profound mitogenic response in rodent liver, and the aim of this study was to characterise the kinetics of induction of DNA synthesis. The CAR ligand, 1,4-bis[2-(3,5-dichoropyridyloxy)]benzene, caused induction of hepatocyte DNA synthesis within 48 hours in 129S4/SvJae mice, but the potent PPAR ligand, ciprofibrate, induced hepatocyte DNA synthesis only after 3 or 4 days dosing; higher or lower doses did not hasten the DNA synthesis response. This contrasted with the rapid induction (24 hours) reported by Styles et al. (Carcinogenesis 9:1647-1655). C57BL/6 and DBA/2J mice showed significant induction of DNA synthesis after 4, but not 2, days ciprofibrate treatment. Alderley Park and 129S4/SvJae mice dosed with methylclofenapate induced hepatocyte DNA synthesis at 4, but not 2, days after dosing, and proved that inconsistency with prior work was not due to a difference in mouse strain or PPARligand. Ciprofibrate-induced liver DNA synthesis and growth was absent in PPAR-null mice, and are PPAR-dependent. In the Fisher344 rat, hepatocyte DNA synthesis was induced at 24 hours after dosing, with a second peak at 48 hours. Lobular localisation of hepatocyte DNA synthesis showed preferential periportal induction of DNA synthesis in rat, but panlobular zonation of hepatocyte DNA synthesis in mouse. These results characterise a markedly later hepatic induction of panlobular DNA synthesis by PPAR ligands in mouse, compared to rapid induction of periportal DNA synthesis in rat.
Introduction
The peroxisome proliferators were originally characterised as a class of structurally diverse compounds that caused liver cancer in rodents {Reddy, 1980 #81}, and induced substantial changes in liver ultrastructure, including proliferation of endoplasmic reticulum and peroxisomes. This class of agents is now known to act through activation of the Peroxisome Proliferator-Activated Receptor  (PPAR) {Issemann, 1990 #70}, and it is clear that this class of carcinogen has a non-genotoxic mode of action {Ashby, 1994 #55; Peters, 1997 #40}. The potent carcinogenicity of this class is shown by the fact that Wy-14,643 can induce 100% multi- The availability of mouse genetic tools {Ledda- Columbano, 2002 #112; Lee, 1995 #53} com- bined with the potent liver growth effect of PPAR ligands in the mouse {Peters, 1997 #40}, provides a compelling reason for using the mouse to characterise the kinetics and mechanisms of induction of hepatocyte DNA synthesis. It is important to characterise the kinetics of induction of DNA synthesis by PPAR ligands in the mouse, as this information is essential for understanding the relationship with genes that regulate the induction of DNA synthesis. The early kinetics of induction of DNA synthesis by PPAR ligands were characterised using flow cytometry to characterise DNA synthesis in rodent liver {Styles, 1987 #80}. Methylclofenapate (MCP) induced high levels of DNA synthesis by as early as 24 hours after dosing in the Alderley Park (AP) mouse {Styles, 1988 #78}, and the kinetics of induction were confirmed by another study in C57BL/6 mice {Styles, 1990 #73}. However, there is one report using immunohisto-
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Page 4 chemical detection of BromodeoxyUridine (BrdU) incorporation in the CD-1 mouse that shows induction of DNA synthesis only after three/ four days of dosing with the potent PPAR ligand, ciprofibrate, {Ledda-Columbano, 2003 #88}, and so this area is in dispute.
Characterisation of the kinetics of induction of DNA synthesis is crucial for understanding the relationship with induced genes that might regulate this response, and so we have examined the time course of induction of hepatocyte DNA synthesis by PPAR ligands in several mouse strains, and in the rat. In contrast to previous reports, we show that there are species-specific kinetics of induction of DNA synthesis, and that the zonation of PPAR ligand-induced DNA synthesis is different between mouse and rat.
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tine from each animal was tested as a positive control. For the determination of zonal distribution of labelled hepatocytes, the method was essentially as described {Barrass, 1993 #92}.
Briefly, a field was defined as a radius of five to seven cells around either the portal space (the periportal region) or the central vein (the perivenous region), using small vessels of similar size.
Five fields were counted for each of the periportal and centrilobular zones for each animal, and the total number of labelled nuclei was recorded.
Statistics. Students t-test was used for comparison of two groups, and a paired t-test for examining body weight loss. ANOVA followed by a post-hoc test (Dunnett's, Newman-Keuls) was used for multiple comparisons. For time-course studies, the control group timepoints were tested to determine if they were significantly different from each other. If not, the control group values were pooled, and the pooled values used for comparisons against the treated groups ( Fig 
Results
Experiments were undertaken to determine whether PPARligands induce hepatic DNA syn- (Fig. 1A) . These doses did increase liver weight at 48 hours after dosing, which was statistically significant (Fig. 1A) , but failed to cause a statistically significant increase in labelling of hepatocyte labelling index (Fig. 1A) .
In order to verify that the chronic BrdU labelling protocol leads to efficient incorporation of BrdU label in liver, as well as intestine, animals were treated with the CAR agonist, 1,4-bis[2-(3,5-dichoropyridyloxy)]benzene (TCPOBOP), at 3 mg kg -1
, which is characterised to cause rapid induction of DNA synthesis in CD-1 mice {Ledda-Columbano, 2003 #88}. There was a statistically significant three-fold increase in ALT in male, but not female, mice (data not shown), showing a small effect on liver cell damage. The liver to body weight ratio was significantly increased in both male and female mice (Fig. 1B) , and the hepatocyte labelling index was induced by TCPOBOP treatment to 25-50% (Fig. 1B,C,D) . Thus the BrdU dosing methodology leads to effective labelling of hepatocyte DNA synthesis that has been induced within 48
hours of xenobiotic (TCPOBOP) treatment in 129S4/SvJae mice; consequently an artefact of dosing methodology can be excluded as a reason for the failure to detect induction of hepatic DNA synthesis in mouse by PPAR ligands (Fig. 1) .
The time course of the hepatic response to ciprofibrate was examined, to determine if the DNA synthesis response occurs at a later stage than in the first two days after dosing. Fig. 2 shows that liver weight is significantly increased as early as 2 days after dosing, and that liver weight has increased by ~100% at 6 days after dosing commenced. The DNA synthesis response was later than the liver growth, with significant induction after three days of administration of ciprofibrate (although with large variation) and subsequently ( Fig. 2A) . In order to ensure that the kinetics of induction of DNA synthesis was not an artefact of too high or low a dose, the hepatocyte DNA synthesis response was examined after three or four days of dosing with ciprofibrate ( Fig. 2B ). As little as 10 mg kg -1 day -1 of ciprofibrate caused a significant increase in liver to body weight ratio, and there was a tendency for the increase in weight to be larger after four days, compared to three days (Fig. 2B ). In this experiment, the induction of DNA synthesis was lower at three days than in the previous experiment ( Fig. 2A,B ), but the induction of DNA synthesis was statistically signficant. At four days after dosing, there was a robust induction of hepatocyte DNA synthesis at 30, or 100 mg kg -1 day -1 of ciprofibrate ( Fig. 2B ), and this latter dose was demonstrated to give the highest induction of DNA synthesis. The hepatic effects of ciprofibrate were examined in female mice to determine if there was a sex difference in response. The liver to body weight ratio was significantly induced after three or four days of dosing ( Fig. 2C ), but hepatocyte DNA synthesis was only significantly increased after four (but not three) days of dosing ( Fig. 2C) , comparable with the male, showing that there is no marked sex difference in induction of hepatocyte DNA synthesis by PPAR ligands. Thus ciprofibrate induced hepatocyte DNA synthesis only after three/ four days of dosing, and the dose giving the highest induction of DNA synthesis has been defined.
These studies had used the 129S4/SvJae mouse, and strain differences were one explanation for the fact that the response seen in (Fig. 2 ) is much later than that reported by Styles {Styles, 1988 #78; Styles, 1990 #73}. Therefore, we investigated the induction of hepatocyte DNA synthesis in C57BL/6J mice; however the results are essentially similar to those seen in 129S4/SvJae mice, with significant induction of hepatocyte DNA synthesis after four (but not two) days of dosing with ciprofibrate ( Fig. 3A) . DBA/2J mice were also dosed using a similar protocol (Fig. 3B) ; liver: body weight ratio is significantly induced at two days after dosing, but the hepatic labelling index is not significantly increased at two days after dosing, but is significantly increased at four and six days after dosing commenced. It is therefore less likely that the discrepancy between this study, and the work of Styles {Styles, 1988 #78; Styles, 1990 #73}, is simply due to an idiosyncracy of the 129S4/SvJae mouse strain, since these workers had shown that methylclofenapate induces hepatocyte DNA synthesis by 24 hours in C57BL/6 mice {Styles, 1990 #73}. In order to exclude the possibility that ciprofibrate may have some effect that is not mediated by the PPAR, the effects of ciprofibrate were tested in congenic 129S4/ SvJae mice which are nullizygous for the PPAR (unpublished data). These data showed that ciprofibrate at 100 mg kg -1 day -1 had no significant effect on liver to body weight ratio, nor on Styles showed rapid induction of hepatic DNA synthesis in Alderley Park (AP) mice, using MCP, and given the importance of this report, we undertook a direct comparison between 129S4/SvJae and AP mice using the same dose of the same peroxisome proliferator (MCP) used by Styles {Styles, 1988 #78}. MCP caused a significant induction of liver growth at days two to four after dosing commenced (Fig. 4A ) in 129S4/SvJae mice, and showed significant induction of hepatocyte DNA synthesis after three or four (but not two) days of dosing (Fig. 4A) ; this is consistent with previous data using the PPAR ligand, ciprofibrate ( Fig. 1-Fig. 3 ). When this experiment was repeated using AP mice, similar results were obtained ( Fig. 4B ): hepatic growth was statistically significant after 2-4 days of dosing, but labelling index was not significantly increased after one, two or three days dosing, and was only statistically significantly increased after four days of dosing with MCP. These data exclude mouse strain or peroxisome proliferator as a cause of the delayed hepatic DNA synthesis response seen with our data, as compared to the results of Styles {Styles, 1988 #78; Styles, 1990 #73} , and provide strong evidence that the induction of hepatic DNA synthesis by PPAR ligands is delayed until after three/ four days in the mouse.
A direct comparison was made with the induction of hepatic DNA synthesis by ciprofibrate in the Fisher 344 rat. Hepatocyte DNA synthesis was significantly increased at 24, 48 and 96 hours after dosing when using the chronic BrdU dosing protocol, attaining a 38% labelling index (Fig. 5A ). The labelling index at the 24 hour time point was significantly different from control (control 1.33 ± 0.37% (mean and SD) versus ciprofibrate 4.4 ± 2.3%) on a t-test. Chronic dosing with BrdU involves exposing animals to the labelling agent for a period of days, thereby leading to a high background value for DNA synthesis in the control group as a result of DNA synthesis over the whole of this period. Therefore, the experiment was repeated using an acute i.p. dose of BrdU at two hours before killing the animals, to characterise the DNA synthesis response within the shorter time frame of the first 48 hours after dosing. The liver weight was slightly, but significantly, increased at 30 and 36 hours after dosing, with a larger increase at 48 hours after dosing with ciprofibrate ( Fig. 5A) . In contrast to the mouse ( Fig. 1-Fig. 4 ), ciprofibrate significantly induced hepatocyte DNA synthesis as early as 24 hours after dosing, with levels falling back to background before a second wave of DNA synthesis at 48 hours after the first dose (Fig. 5B) . The induction of hepatocyte DNA synthesis at 24 hours was examined by varying the dose of ciprofibrate, confirming an early induction of hepatocyte DNA synthesis at 24 hours, and further showing that 50-200 mg ciprofibrate kg -1 bodyweight are optimal doses for inducing hepatocyte DNA synthesis (Fig. 5C ). At 300 mg ciprofibrate kg -1 bodyweight, there is no significant induction of liver to bodyweight ratio, and no induction of hepatocyte DNA synthesis; the diminished nature of these responses, compared with lower doses, suggests that 300 mg kg -1 bodyweight is overtly toxic and is suppressing the liver growth response. These results demonstrate that there is a species difference between mouse and rat in the kinetics of induction of hepatocyte DNA synthesis by PPAR ligands.
Given these distinct results in mouse and rat, the lobular zonation of induction of hepatocyte DNA synthesis in liver was examined, as previously described {Barrass, 1993 #92}. Fig. 6A shows that there is marked periportal distribution of labelled hepatocyte nuclei in the rat, whereas the mouse shows a pan-lobular distribution of labelled cells. Quantification of these data (Fig. 6B) shows that there is a difference in the zonation of induced hepatocyte DNA synthesis between the rat and mouse, with statistically significant preferential periportal induction of DNA synthesis by PPAR ligands in the Fisher344 rat, and no significant difference between periportal and centrilobular induction of DNA synthesis in the 129S4/SvJae mouse. The data in Fig. 6B are typical of data from 129S4/SvJae mice treated with 30-100 mg ciprofibrate kg -1 day -1 for three or four days, 100 mg ciprofibrate kg -1 day -1 for three to 6 days, 25 mg kg -1 day -1 methylclofenapate for three or four days, or C57BL/6 mice treated with 100 mg ciprofibrate kg -1 day -1 for four days (Data not shown). Likewise, the preferential periportal distribution of induced DNA synthesis in rat hepatocytes is consistent over a dose range of 50-200 mg ciprofibrate kg -1 , and when using a chronic BrdU administration regime (data not shown).
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Discussion
The mouse and rat show differential kinetics of induction of hepatocyte DNA synthesis after exposure to PPAR ligands, with the mouse response being delayed to three days after dosing. cate the results of Styles in both mouse strains; while it is possible that the AP mice, being outbred, may have undergone strain drift, the C57BL/6 mice are inbred, and are unlikely to show significant strain drift. Moreover, the concordance between the results obtained in 129S4/SvJae, AP, C57BL/6J and DBA/2J mice in our hands excludes the possibility that the discordance between our data, and those of Styles {Styles, 1988 #78; Styles, 1990 #73}, arises from mouse strain differences.
The possibility that ciprofibrate had off-target (i.e. non-PPAR mediated) effects that confounded its liver growth function was also considered. Ciprofibrate is a potent PPAR ligand {Mukherjee, 2002 #219}, has similar effects to another potent {Bell, 1991 #67; Bell, 1991 #65}
PPARligand, MCP, and the use of PPAR-nullizygous mice provides compelling evidence that the liver growth and DNA synthesis effects of ciprofibrate are mediated by the PPAR.
It is difficult to explain the difference in kinetics of induction of DNA synthesis reported by Styles {Styles, 1988 #78; Styles, 1990 #73} , and in this study. Table 1 The definition of the rapid induction of hepatocyte DNA synthesis in rat by PPAR ligands opens up opportunities for investigating the mechanism of induction of the growth response, by relating the early gene induction events to subsequent hyperplasia. There is evidence that the liver growth programme induced by PPAR ligands is quite distinct from that seen during regeneration or after treatment with growth factors e.g. {Menegazzi, 1997 #124; Plant, 1998 #35;
Plant, 1998 #39}: the PPAR-ligand induced growth defined in this paper offers a tractable system for investigating how augmentative liver growth is regulated. 
